The likelihood of long COVID, claims costs, and claim duration all increased with the severity of acute COVID-19.
The only pre-exposure prophylactic for COVID-19 may not provide protection for certain variants.
Moderna and Pfizer boosters have been updated to target the omicron variant.
Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.
Drug advancements surrounding the prevention and treatment of COVID-19.
Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.
All adults may now receive a booster shot of any COVID-19 vaccine.
All COVID-19 vaccines now have emergency use authorization for a booster dose.
Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.